Windtree Therapeutics Inc
WINT- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946486
No open-market purchases or sales by Windtree Therapeutics Inc insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Windtree Therapeutics Inc changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 9 | 5 | −4 |
| Shares | 674.6K | 1.52K | −673.1K (−99.8%) |
| Value | $238.8K | $4.87K | −$233.9K (−98.0%) |
New holders (3)
Institutions that held Windtree Therapeutics Inc at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tower Research Capital LLC (TRC) | 1,506 | $4.83K | 0.00% |
| Bank of America Corp | 4 | $13 | 0.00% |
| Activest Wealth Management | 2 | $6 | 0.00% |
Sold out (7)
Institutions that held Windtree Therapeutics Inc at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 608,272 | $215.3K |
| Vanguard Group Inc | 41,640 | $14.7K |
| Geode Capital Management, LLC | 13,991 | $4.95K |
| Citadel Advisors LLC | 10,655 | $3.77K |
| Wells Fargo & Company | 41 | $15 |
| US Bancorp | 3 | $1 |
| Advisor Group Holdings, Inc. | 1 | $0 |